Kewaunee Scientific Corporation
KEQU
#9391
Rank
$0.10 B
Marketcap
$36.48
Share price
-1.41%
Change (1 day)
12.18%
Change (1 year)

Kewaunee Scientific Corporation - 10-Q quarterly report FY2012 Q2


Text size:
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2011

or

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                    to                     

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

 28677-2927
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨  Accelerated filer ¨
Non-accelerated filer ¨  (Do not check if a smaller reporting company)  Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of December 5, 2011, the registrant had outstanding 2,579,464 shares of Common Stock.

 

 

 


Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2011

 

     Page Number 

PART I. FINANCIAL INFORMATION

  

Item 1.

 Financial Statements  
 Consolidated Statements of Operations (unaudited) – Three and six months ended October 31, 2011 and 2010   1  
 Consolidated Balance Sheets – October 31, 2011 (unaudited) and April 30, 2011   2  
 Consolidated Statements of Cash Flows (unaudited) – Six months ended October 31, 2011 and 2010   3  
 Notes to Consolidated Financial Statements   4  

Item 2.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations   7  
 Review by Independent Registered Public Accounting Firm   9  
 Report of Independent Registered Public Accounting Firm   10  

Item 3.

 Quantitative and Qualitative Disclosures About Market Risk   11  

Item 4.

 Controls and Procedures   11  

PART II. OTHER INFORMATION

  

Item 6.

 Exhibits   12  

SIGNATURE

   13  

 

 

i


Table of Contents

Part 1. Financial Information

Item  1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

   Three months ended
October 31
  Six months ended
October 31
 
   2011  2010  2011  2010 

Net Sales

  $25,962   $25,625   $52,283   $50,483  

Costs of products sold

   22,117    20,208    44,250    40,067  
  

 

 

  

 

 

  

 

 

  

 

 

 

Gross profit

   3,845    5,417    8,033    10,416  

Operating expenses

   4,005    4,045    7,960    7,946  
  

 

 

  

 

 

  

 

 

  

 

 

 

Operating earnings (loss)

   (160  1,372    73    2,470  

Other income (expense)

   36    (1  35    (1

Interest expense

   (128  (77  (223  (122
  

 

 

  

 

 

  

 

 

  

 

 

 

Earnings (loss) before income taxes

   (252  1,294    (115  2,347  

Income tax expense (benefit)

   (96  414    (67  743  
  

 

 

  

 

 

  

 

 

  

 

 

 

Net earnings (loss)

   (156  880    (48  1,604  

Less: net earnings (loss) attributable to the noncontrolling interest

   (31  25    55    92  
  

 

 

  

 

 

  

 

 

  

 

 

 

Net earnings (loss) attributable to Kewaunee Scientific Corporation

  $(125 $855   $(103 $1,512  
  

 

 

  

 

 

  

 

 

  

 

 

 

Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders

     

Basic

  $(0.05 $0.33   $(0.04 $0.59  

Diluted

  $(0.05 $0.33   $(0.04 $0.59  

Weighted average number of common shares outstanding

     

Basic

   2,579    2,573    2,579    2,573  

Diluted

   2,579    2,578    2,579    2,578  

See accompanying notes to consolidated financial statements.

 

1


Table of Contents

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

   October 31,
2011
  April 30,
2011
 
   (Unaudited)    

Assets

   

Current Assets:

   

Cash and cash equivalents

  $3,212   $2,402  

Restricted cash

   876    553  

Receivables, less allowance

   23,479    27,346  

Inventories

   10,370    10,466  

Deferred income taxes

   495    431  

Prepaid expenses and other current assets

   1,583    1,181  
  

 

 

  

 

 

 

Total Current Assets

   40,015    42,379  

Property, plant and equipment, at cost

   43,220    42,716  

Accumulated depreciation

   (27,237  (26,141
  

 

 

  

 

 

 

Net Property, Plant and Equipment

   15,983    16,575  

Deferred income taxes

   459    399  

Other

   3,653    3,705  
  

 

 

  

 

 

 

Total Other Assets

   4,112    4,104  
  

 

 

  

 

 

 

Total Assets

  $60,110   $63,058  
  

 

 

  

 

 

 

Liabilities and Equity

   

Current Liabilities:

   

Short-term borrowings

  $7,326   $6,588  

Current obligations under capital leases

   79    83  

Current portion of long-term debt

   200    200  

Accounts payable

   6,626    9,770  

Employee compensation and amounts withheld

   1,565    1,435  

Deferred revenue

   1,061    1,108  

Other accrued expenses

   1,619    1,080  
  

 

 

  

 

 

 

Total Current Liabilities

   18,476    20,264  

Obligations under capital leases

   —      36  

Long-term debt

   3,567    3,667  

Accrued employee benefit plan costs

   5,892    6,075  
  

 

 

  

 

 

 

Total Liabilities

   27,935    30,042  

Commitments and Contingencies

   

Equity:

   

Common Stock

   6,550    6,550  

Additional paid-in-capital

   1,215    1,091  

Retained earnings

   28,599    29,218  

Accumulated other comprehensive loss

   (5,259  (4,930

Common stock in treasury, at cost

   (429  (438
  

 

 

  

 

 

 

Total Kewaunee Scientific Corporation Stockholders’ Equity

   30,676    31,491  

Noncontrolling interest

   1,499    1,525  
  

 

 

  

 

 

 

Total Equity

   32,175    33,016  
  

 

 

  

 

 

 

Total Liabilities and Equity

  $60,110   $63,058  
  

 

 

  

 

 

 

See accompanying notes to consolidated financial statements.

 

2


Table of Contents

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

   Six months ended
October 31
 
   2011  2010 

Cash flows from operating activities:

   

Net earnings (loss)

  $(48 $1,604  

Adjustments to reconcile net earnings (loss) to net cash used in operating activities:

   

Depreciation

   1,343    1,189  

Bad debt provision

   16    85  

Provision for deferred income tax expense (benefit)

   (124  (164

Increase in prepaid income taxes

   (103  —    

Decrease (increase) in receivables

   3,851    (909

Decrease (increase) in inventories

   96    (708

Decrease in accounts payable and other accrued expenses

   (2,475  (18

(Decrease) increase in deferred revenue

   (47  313  

Other, net

   (583  (913
  

 

 

  

 

 

 

Net cash provided by operating activities

   1,926    479  

Cash flows from investing activities:

   

Capital expenditures

   (751  (3,712

Increase in restricted cash

   (323  —    
  

 

 

  

 

 

 

Net cash used in investing activities

   (1,074  (3,712

Cash flows from financing activities:

   

Proceeds from long-term debt

   —      4,000  

Payments on long-term debt

   (100  (33

Dividends paid

   (516  (514

Decrease (increase) in short-term borrowings

   738    (725

Payments on capital leases

   (40  (42

Net proceeds from exercise of stock options (including tax benefit)

   —      (1
  

 

 

  

 

 

 

Net cash provided by financing activities

   82    2,685  

Effect of exchange rate changes on cash

   (124  74  
  

 

 

  

 

 

 

Increase (decrease) in cash and cash equivalents

   810    (474

Cash and cash equivalents, beginning of period

   2,402    1,722  
  

 

 

  

 

 

 

Cash and cash equivalents, end of period

  $3,212   $1,248  
  

 

 

  

 

 

 

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2011 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Inventories

Inventories consisted of the following (in thousands):

 

   October 31, 2011   April 30, 2011 

Finished products

  $3,159    $2,887  

Work in process

   1,506     1,697  

Raw materials

   5,705     5,882  
  

 

 

   

 

 

 
  $10,370    $10,466  
  

 

 

   

 

 

 

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

C. Comprehensive Income (Loss)

A reconciliation of net earnings and total comprehensive income for the three and six months ended October 31, 2011 and 2010 is as follows (in thousands):

 

   Three months ended
October 31, 2011
  Three months ended
October 31, 2010
 

Net earnings (loss)

  $(125 $855  

Change in cumulative foreign currency translation adjustments

   (279  98  

Change in fair value of cash flow hedge, net of tax

   (39  (197
  

 

 

  

 

 

 

Total comprehensive income (loss)

  $(443 $756  
  

 

 

  

 

 

 
   Six months ended
October 31, 2011
  Six months ended
October 31, 2010
 

Net earnings (loss)

  $(103 $1,512  

Change in cumulative foreign currency translation adjustments

   (235  (18

Change in fair value of cash flow hedge, net of tax

   (94  (208
  

 

 

  

 

 

 

Total comprehensive income (loss)

  $(432 $1,286  
  

 

 

  

 

 

 

 

4


Table of Contents

Assets and liabilities for the Company’s foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in stockholders’ equity.

D. Segment Information

The following table provides financial information by business segments for the three and six months ended October 31, 2011 and 2010 (in thousands):

 

   Domestic
Operations
   International
Operations
  Corporate  Total 

Three months ended October 31, 2011

      

Revenues from external customers

  $23,826    $2,136   $—     $25,962  

Intersegment revenues

   128     94    (222  —    

Operating earnings (loss) before income taxes

   650     (43  (859  (252

Three months ended October 31, 2010

      

Revenues from external customers

  $22,269    $3,356   $—     $25,625  

Intersegment revenues

   504     4    (508  —    

Operating earnings (loss) before incomes taxes

   2,112     105    (923  1,294  

 

   Domestic
Operations
   International
Operations
   Corporate  Total 

Six months ended October 31, 2011

       

Revenues from external customers

  $47,222    $5,061    $—     $52,283  

Intersegment revenues

   401     266     (667  —    

Operating earnings (loss) before income taxes

   1,367     200     (1,682  (115

Six months ended October 31, 2010

       

Revenues from external customers

  $43,216    $7,267    $—     $50,483  

Intersegment revenues

   1,167     647     (1,814  —    

Operating earnings (loss) before incomes taxes

   3,697     333     (1,683  2,347  

E. Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. Contributions of $402,000 were paid to the plans during the six months ended October 31, 2011, and the Company does not expect any contributions to be paid to the plans during the remainder of the fiscal year. Contributions of $719,000 were made during the six months ended October 31, 2010 of the prior year.

Pension expense consisted of the following (in thousands):

 

   Three months ended
October 31, 2011
  Three months ended
October 31, 2010
 

Service cost

  $ -0-   $ -0-  

Interest cost

   235    240  

Expected return on plan assets

   (326  (289

Recognition of net loss

   179    172  
  

 

 

  

 

 

 

Net periodic pension expense

  $88   $123  
  

 

 

  

 

 

 
   Six months ended
October 31, 2011
  Six months ended
October 31, 2010
 

Service cost

  $ -0-   $ -0-  

Interest cost

   470    480  

Expected return on plan assets

   (652  (578

Recognition of net loss

   358    344  
  

 

 

  

 

 

 

Net periodic pension expense

  $176   $246  
  

 

 

  

 

 

 

 

5


Table of Contents

F. Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding during the three and six month periods. Diluted earnings per share reflects the assumed exercise and conversion of outstanding options under the Company’s stock option plans, except when options have an anti-dilutive effect. Options to purchase shares of 325,300 were not included in diluted earnings per share for the three and six month periods ended October 31, 2011, because the effect would be anti-dilutive.

G. Reclassifications

Certain 2010 amounts have been reclassified to conform with the 2011 presentation in the consolidated statements of cash flows. Such reclassifications had no impact on net earnings.

 

6


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2011 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2011. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2011. The analysis of results of operations compares the three and six months ended October 31, 2011 with the comparable period of the prior year.

Results of Operations

Sales for the three months ended October 31, 2011 were $25,962,000, an increase of 1.3% from sales of $25,625,000 in the comparable period of the prior year. Sales from Domestic Operations were $23,826,000, up from $22,269,000 in the comparable period of the prior year. The increase was primarily due to the continued demand for larger laboratory projects, although at extremely competitive prices. Sales from International Operations were $2,136,000, down from $3,356,000 in the comparable period of the prior year. The decrease in international sales was primarily due to building construction delays for several projects in the Company’s order backlog.

Sales for the six months ended October 31, 2011 were $52,283,000, up 3.6% from sales of $50,483,000 in the same period last year. Domestic operations sales were $47,222,000, up from sales of $43,216,000 in the same period last year. International operation sales were $5,061,000, down from sales of $7,267,000 in the same period last year.

The order backlog was $78.0 million at October 31, 2011, as compared to $65.7 million at April 30, 2011 and $66.0 million at October 31, 2010.

The gross profit margin for the three months ended October 31, 2011 was 14.8% of sales, as compared to 21.1% of sales in the comparable quarter of the prior year. The gross profit margin for the six months ended October 31, 2011 was 15.4% of sales, as compared to 20.6% of sales in the comparable period of the prior year. The decrease in the gross profit margin percentages was primarily due to lower selling prices due to the extremely-competitive marketplace and higher costs paid for raw materials, particularly steel and epoxy resin.

Operating expenses for the three months ended October 31, 2011 were $4,005,000, or 15.4% of sales, as compared to $4,045,000, or 15.8% of sales, in the comparable period of the prior year. Operating expenses for the six months ended October 31, 2011 were $7,960,000, or 15.2% of sales, as compared to $7,946,000, or 15.7% of sales in the comparable period of the prior year. Expenses for both periods of the current year were relatively flat with the comparable periods of the prior year as higher sales and marketing costs were offset by lower administrative expenses. Expenses as a percentage of sales declined in both periods of the current years, as sales increased 1.3% and 3.6%, respectively for the three and six month periods ended October 31, 2011.

Interest expense was $128,000 and $223,000 for the three and six months ended October 31, 2011, as compared to $77,000 and $122,000 for the comparable periods of the prior year. The increase for the current year period resulted from the addition of long-term debt used to finance the expansion of the Company’s Statesville facilities in fiscal year 2011.

An income tax benefit of $96,000 was recorded for the three months ended October 31, 2011, as compared to income tax expense of $414,000 recorded for the comparable period of the prior year. An income tax benefit of $67,000 was recorded for the six months ended October 31, 2011, as compared to an income tax expense of $743,000 recorded for the comparable period of the prior year. The effective tax rate was 38.1% for the three months ended October 31, 2011, and 32.0% for the comparable period of the prior year. The effective tax rates were 58.3% and 31.7% for the six months ended October 31, 2011 and 2010, respectively. The effective tax rate for the current year periods benefited from the favorable impact of federal and state income tax credits combined with the reported net loss.

Noncontrolling interests related to the Company’s two subsidiaries that are not 100% owned by the Company increased net earnings by $31,000 for the three months ended October 31, 2011, as compared to a reduction of net earnings by $25,000 for the comparable period of the prior year. Net earnings were reduced by $55,000 and $92,000 for the six months ended October 31, 2011 and 2010, respectively. The changes in the net earnings attributable to the noncontrolling interest in the current periods were due to the earnings of the two subsidiaries.

A net loss of $125,000, or $0.05 per diluted share, was reported for the three months ended October 31, 2011, compared to net earnings of $855,000, or $0.33 per diluted share, in the prior year period. A net loss of $103,000, or $0.04 per diluted share, was reported for the six months ended October 31, 2011, compared to net earnings of $1,512,000, or $0.59 per diluted share, for the same period last year.

 

7


Table of Contents

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $21.5 million at October 31, 2011, compared to $22.1 million at April 30, 2011. The ratio of current assets to current liabilities was 2.2-to-1.0 at October 31, 2011, compared to 2.1-to-1.0 at April 30, 2011. At October 31, 2011, advances of $7,326,000 were outstanding under the Company’s bank revolving credit facility, as compared to advances of $6,588,000 outstanding as of April 30, 2011. Total bank borrowings and capital lease obligations were $11,172,000 at October 31, 2011, as compared to $10,574,000 at April 30, 2011.

The Company’s operations provided cash of $1,926,000 during the six months ended October 31, 2011. Cash was primarily provided from earnings and a decrease in accounts receivable of $3,851,000, which was partially offset by a decrease in accounts payable and other accrued expenses of $2,475,000. The Company’s operations provided cash of $479,000 during the six months ended October 31, 2010, with cash primarily provided from earnings, which was partially offset by increased accounts receivable of $909,000 and an increase in inventory of $708,000.

During the six months ended October 31, 2011, net cash of $1,074,000 was used in investing activities, primarily for capital expenditures. This compares to the use of $3,712,000 for investing activities in the comparable period of the prior year, primarily for capital expenditures, related to the expansion of the Company’s Statesville, North Carolina manufacturing facilities.

The Company’s financing activities provided cash of $82,000 during the six months ended October 31, 2011. Cash provided included $738,000 received from short-term borrowings, partially offset by cash dividends of $516,000 paid to stockholders. Financing activities provided cash of $2,685,000 in the same period of the prior year, primarily from the proceeds from $4,000,000 in long-term debt, partially offset by cash dividends paid of $514,000, and repayment of short-term borrowings of $725,000. The proceeds of the term loan were used primarily to fund the expansion of the Company’s Statesville, North Carolina manufacturing facilities.

Outlook for Fiscal Year 2012

The Company’s ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers for subcontractors, and the fact that demand for its products is dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. Customer changes to product designs and delivery dates for orders may also delay the start of manufacturing and shipment of orders, which in return may impact the timing of sales revenue and increase manufacturing costs.

The Company’s current expectations are that sales and earnings for fiscal year 2012 will improve modestly over fiscal year 2011. These expectations are based on scheduled shipments of international orders in the backlog, cost savings initiatives in process, increased sales through the Company’s strengthened and expanding dealer network, growing benefits from new product lines, and sales and earnings from new products.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, customer changes to product designs, customer changes to delivery dates, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such difference might be significant and harmful to stockholders’ interests. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of the Company’s 2011 Annual Report on Form 10-K.

 

8


Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three and six month periods ended October 31, 2011 and October 31, 2010 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company’s independent registered public accounting firm. Their report on the interim consolidated financial information follows.

 

9


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of October 31, 2011, and the related consolidated statements of operations for the three month and six month periods ended October 31, 2011 and 2010 and the related consolidated statements of cash flows for the six-month periods ended October 31, 2011 and 2010. These interim consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2011, and the related statements of operations, of stockholders’ equity and of cash flows for the year then ended (not presented herein) and in our report dated July 15, 2011, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2011 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

 

/s/ Cherry, Bekaert & Holland, L.L.P.     
Charlotte, North Carolina

December 12, 2011

 

10


Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2011.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of October 31, 2011. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of October 31, 2011, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

11


Table of Contents

PART II. OTHER INFORMATION

Item 6. Exhibits

 

 10.1  Amendment No. 1 to Amended and Restated Loan and Security Agreement, dated August 25, 2011 (1).
 10.2  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of William A. Shumaker. *(1)
 10.3  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of D. Michael Parker. *(1)
 10.4  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of Kurt P. Rindoks. *(1)
 10.5  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of David M. Rausch. *(1)
 10.6  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of Dana L. Dahlgren. *(1)
 10.7  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of K. Bain Black. *(1)
 10.8  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of Keith D. Smith. *(1)
 10.9  Extension Agreement, dated August 24, 2011, with respect to the Change of Control Employment Agreement of Elizabeth D. Phillips. *(1)
 31.1  Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 31.2  Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 32.1  Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 32.2  Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS  XBRL Instance Document
101.SCH  XBRL Taxonomy Extension Schema Document
101.CAL  XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB  XBRL Taxonomy Extension Label Linkbase Document
101.PRE  XBRL Taxonomy Extension Presentation Linkbase Document

 

*The referenced exhibit is a management contract or compensatory plan or arrangement.
(1)Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed on August 30, 2011, and incorporated herein by reference.

 

12


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  

KEWAUNEE SCIENTIFIC CORPORATION

                        (Registrant)

Date: December 13, 2011  By /s/ D. Michael Parker
   D. Michael Parker
   (As duly authorized officer and Senior Vice President, Finance and Chief Financial Officer)

 

13